The cumulative incidences at @ months of intestinal GvHD stage > @ with death as a competing event ( budesonide @ % vs. placebo @ % , p = @ ) and the cumulative incidence of relapse ( budesonide @ % vs. placebo @ % , p = @ ) and non-relapse mortality ( budesonide @ % ( @ % CI @-@ % ) vs. placebo @ % ( @ % CI @-@ % ) , showed no significant difference within the two groups ( p = @ ) .